Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
Sponsor: Climb Bio, Inc.
Summary
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose (SAD) and Multiple-Ascending-Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection(s) of CLYM116 in Normal Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2025-12-02
Completion Date
2026-09
Last Updated
2026-02-20
Healthy Volunteers
Yes
Conditions
Interventions
CLYM116
CLYM116 to be administered by SC injection
Placebo
Placebo solution to be administered at a matching volume by SC injection
Locations (1)
Nucleus Network Brisbane
Brisbane, Australia